aTyr Pharma Inc (ATYR)

Currency in USD
0.778
0.000(0.00%)
Real-time Data·

ATYR Earnings

Latest Release
Nov 06, 2025
EPS / Forecast
-0.26 / -0.17
Revenue / Forecast
190.00K / 1.33M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
12/2025--/-0.178--/22.22K----Free Sign Up
09/2025-0.26/-0.17190K/1.33M-52.94%-85.71%Free Sign Up
06/2025-0.22/-0.185--/---19.24%--Free Sign Up
03/2025-0.17/-0.19--/--+10.53%--Free Sign Up
12/2024-0.18/-0.23--/--+21.74%--Free Sign Up
09/2024-0.23/-0.22--/21.67K-4.55%-100%Free Sign Up
06/2024-0.23/-0.25--/--+8%--Free Sign Up
03/2024-0.23/-0.24240K/27.5K+4.17%+772.73%Free Sign Up
12/2023-0.25/-0.24260K/3.42M-4.17%-92.4%Free Sign Up
09/2023-0.2/-0.2353K/353K0%0%Free Sign Up

All numbers in USD

aTyr Pharma Inc Earnings Call Summary for Q4/2024

  • aTyr Pharma Q4 2024 EPS of -$0.18 beat expectations of -$0.23, with $75.1M cash on hand and $200K revenue from collaborations
  • Phase III EFSOFIT study enrollment completed; top-line data expected Q3 2024 for lead candidate Esofitamod in pulmonary sarcoidosis
  • Stock rose 12.39% in regular trading but fell 9.77% after hours; analysts maintain strong buy consensus with $9-$35 price targets
  • R&D expenses of $54.4M reflect ongoing investment in therapeutic candidates; company exploring additional indications and pipeline development
  • CEO Sanjay Shukla emphasized scientific advancements and potential impact across medical fields; EFSOFIT study maintains 90% statistical power
Last Updated: 13/03/2025, 23:18
Read Full Transcript

FAQ

What Is aTyr Pharma's Earnings Per Share (TTM)?

The aTyr Pharma EPS (TTM) is -0.84.

What Is aTyr Pharma Revenue For The Last Quarter?

aTyr Pharma's revenue for the last quarter was 0.19.

When Is The Next aTyr Pharma Earnings Date?

aTyr Pharma will release its next earnings report on 11 Mar 2026.

What Is aTyr Pharma’s Revenue Forecasts For Upcoming Quarters?

aTyr Pharma’s revenue forecast is 22.22K.

How Did aTyr Pharma React to the Company's Latest Earnings Report?

aTyr Pharma reported a -52.94%% EPS surprise and a -85.71%% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 0.380%%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.